Skip to content

What is the drug Granitron (Granisetron) used for? A guide to its antiemetic applications.

4 min read

Granisetron, a potent antiemetic agent often referenced by the potential misspelling Granitron, has been FDA-approved since 1993 and is commonly known by brand names like Kytril, Sancuso, or Sustol. This medication is primarily used to manage severe nausea and vomiting associated with cancer treatments and surgical procedures.

Quick Summary

Granisetron is a 5-HT3 receptor antagonist prescribed to prevent and treat nausea and vomiting triggered by chemotherapy, radiation therapy, and postoperative recovery. It works by blocking serotonin signals that cause the vomiting reflex.

Key Points

  • Antiemetic Medication: Granisetron is the proper name for the drug often referred to as Granitron, and it is used to prevent and treat nausea and vomiting.

  • Blocking Serotonin Receptors: Its mechanism of action involves blocking 5-HT3 serotonin receptors in the gut and brain, which are responsible for triggering the vomiting reflex.

  • Multiple Indications: Granisetron is effective for managing nausea and vomiting caused by chemotherapy (CINV), radiation therapy (RINV), and surgical procedures (PONV).

  • Variety of Forms: The medication is available as oral tablets, intravenous injections, and extended-release patches and subcutaneous injections to suit different treatment protocols.

  • Risk of Serious Side Effects: Key safety concerns include the potential for heart rhythm changes (QT prolongation) and the risk of serotonin syndrome when combined with other serotonergic drugs.

  • Distinction from Ondansetron: While both are 5-HT3 antagonists, Granisetron offers a longer half-life and less frequent dosing compared to Ondansetron (Zofran), though it may be more expensive.

  • Important Interactions: Serious drug interactions can occur, particularly with other medications that affect serotonin levels or heart rhythm. Concurrent use with apomorphine is contraindicated.

In This Article

What is Granitron (Granisetron) and how does it work?

Granisetron is the correct spelling for the drug sometimes referred to as Granitron. It belongs to a class of medications called 5-HT3 receptor antagonists. It is used to prevent and treat nausea and vomiting by targeting the signals that trigger these symptoms in the body. The primary substance involved in this process is serotonin, a neurotransmitter that can stimulate the brain's vomiting center.

Mechanism of Action

  • Blocking Serotonin: When certain treatments like chemotherapy or radiation are administered, or after surgical procedures, cells in the gastrointestinal tract and vagus nerve can release serotonin.
  • Inhibiting Receptors: Granisetron works by blocking the 5-HT3 serotonin receptors, preventing the serotonin from binding and sending signals to the brain that cause nausea and vomiting.
  • Interrupting the Reflex: By inhibiting this crucial step, granisetron effectively interrupts the vomiting reflex pathway, providing relief to patients.

Primary uses for Granisetron

Granisetron is prescribed to manage specific types of nausea and vomiting in clinical settings. Its effectiveness has made it a key medication for patients undergoing intensive medical procedures. The main indications include:

  • Chemotherapy-Induced Nausea and Vomiting (CINV): This is one of the most common applications for granisetron. It is used to prevent the immediate and delayed nausea and vomiting caused by emetogenic (vomit-inducing) chemotherapy, including high-dose regimens.
  • Radiation Therapy-Induced Nausea and Vomiting (RINV): Patients receiving radiation therapy, especially to the abdomen or for total body irradiation, can experience significant nausea and vomiting. Granisetron helps prevent these side effects.
  • Postoperative Nausea and Vomiting (PONV): The medication is also used to prevent and treat nausea and vomiting that can occur after surgical procedures in adults.

Forms of Administration

Granisetron is available in several formulations to suit different clinical needs and patient conditions:

  • Oral Tablets: Taken by mouth, usually within an hour before chemotherapy or radiation treatment.
  • Intravenous (IV) Injection: Administered directly into a vein by a healthcare professional, often shortly before chemotherapy or surgery.
  • Transdermal Patch (Sancuso): A single patch applied to the skin, typically worn for up to seven days, to provide continuous nausea prevention during chemotherapy cycles.
  • Extended-Release Subcutaneous (SC) Injection (Sustol): A long-acting injection for adults to prevent delayed CINV. It is given with other antiemetics and can last for several days.

Granisetron vs. Ondansetron (Zofran)

Granisetron and ondansetron are both popular 5-HT3 receptor antagonists, but they have some key differences that can influence a doctor's choice.

Feature Granisetron (Kytril, Sancuso, Sustol) Ondansetron (Zofran)
Mechanism of Action Blocks 5-HT3 serotonin receptors Blocks 5-HT3 serotonin receptors
Half-Life Longer half-life (approx. 9 hours) Shorter half-life (approx. 4 hours)
Dosing Frequency Typically dosed once or twice daily on treatment days, extended-release formulations available Often requires multiple doses throughout the day (e.g., every 8 to 12 hours)
Indications CINV, RINV, PONV CINV, RINV, PONV
Cost Can be more expensive than ondansetron Available as a lower-cost generic
Administration Forms Oral tablets, IV, transdermal patch, extended-release SC Oral tablets, orally disintegrating tablets, oral solution, IV

Common side effects and risks

Like all medications, granisetron can cause side effects. Most are mild and manageable, but some can be serious and require immediate medical attention.

Common side effects include:

  • Headache
  • Constipation or diarrhea
  • Abdominal pain
  • Weakness or lack of energy
  • Difficulty sleeping or drowsiness

Serious risks and warnings include:

  • Serotonin Syndrome: A potentially life-threatening condition that can occur when granisetron is taken with other serotonergic drugs like SSRIs and SNRIs. Symptoms can include agitation, confusion, fever, muscle rigidity, and rapid heartbeat.
  • Heart Rhythm Changes (QT Prolongation): Granisetron can prolong the QT interval, which can lead to serious arrhythmias. Patients with pre-existing heart conditions, electrolyte imbalances, or those taking other medications that affect heart rhythm are at higher risk.
  • Masking of Underlying Conditions: Because granisetron reduces nausea and vomiting, it can mask symptoms of other underlying gastrointestinal problems, such as a bowel blockage, which is a concern after abdominal surgery.
  • Allergic Reactions: Severe allergic reactions, including anaphylaxis, can occur.

Important drug interactions and contraindications

Patients should inform their healthcare provider of all medications and medical conditions before taking granisetron. Significant drug interactions and contraindications exist.

Drug Interactions

  • Serotonergic Drugs: Concomitant use with SSRIs (e.g., fluoxetine), SNRIs (e.g., venlafaxine), MAOIs, tramadol, and intravenous methylene blue increases the risk of serotonin syndrome.
  • QT-Prolonging Drugs: Caution is advised with other medications that prolong the QT interval, such as certain antiarrhythmics, antipsychotics, and antidepressants.
  • Apomorphine: Concomitant use with apomorphine (used for Parkinson's disease) is contraindicated due to a risk of profound hypotension and loss of consciousness.

Contraindications

  • Hypersensitivity: Patients with a known allergy to granisetron or other 5-HT3 receptor antagonists should not use this medication.
  • Bowel Blockage: Caution is necessary in patients with a potential bowel blockage, as granisetron can mask the symptoms.

Conclusion

Granisetron, correctly spelled, is a highly effective antiemetic medication for managing nausea and vomiting associated with chemotherapy, radiation therapy, and surgical procedures. By targeting serotonin receptors, it provides significant relief to patients undergoing challenging medical treatments. While generally well-tolerated, it is crucial to be aware of potential side effects, particularly the risk of heart rhythm changes and serotonin syndrome, especially when taking other medications. Always consult a healthcare provider to ensure granisetron is the appropriate treatment option for your specific situation.

Frequently Asked Questions

Granitron is a common misspelling of the prescription medication Granisetron. The correct spelling, Granisetron, is the active ingredient in several antiemetic products, such as Kytril, Sancuso, and Sustol.

Granisetron is primarily used to prevent and treat nausea and vomiting caused by cancer treatments like chemotherapy and radiation therapy. It is also used to prevent and treat postoperative nausea and vomiting after surgery.

Granisetron works by blocking the action of serotonin on 5-HT3 receptors. Serotonin is a natural substance that stimulates the brain's vomiting center. By blocking these receptors, granisetron helps to interrupt the signals that cause nausea and vomiting.

The most common side effects of granisetron include headache, constipation or diarrhea, abdominal pain, and weakness or fatigue.

Yes, serious side effects can occur, including heart rhythm changes (QT prolongation) and serotonin syndrome. It is important to inform your doctor if you have heart problems or are taking other medications that affect heart rhythm or serotonin levels.

Granisetron is available in several forms, including oral tablets, intravenous (IV) injections, and transdermal patches. An extended-release subcutaneous (SC) injection is also available for delayed nausea.

There are no adequate and well-controlled studies on granisetron in pregnant women. Caution should be exercised when administering it to a nursing mother, as it is unknown if the drug is excreted in human milk.

Granisetron can interact with other drugs. It should not be taken with apomorphine. Special caution is needed when combining it with other serotonergic medications or drugs that can affect heart rhythm due to the risk of serotonin syndrome or QT prolongation.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice.